Michael Hartmann
Research Subjects
Michael Hartmann has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Cote
Process Research & Development MRL, Merck & Co., Inc. Rahway New Jersey USA
1 shared publication - Chengbei Li
Merck & Co., Inc
1 shared publication David Roush
Downstream Biologics Process Research and Development, Merck & Co., Inc. Rahway, NJ 07065, USA
1 shared publication- Guangli Hu
Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc, Rahway, USA
1 shared publication - Jeffrey C. Givand
Merck & Co., Inc
1 shared publication - Jing Song
Merck & Co., Inc
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanistic Investigation of Zn (II) Extraction and Interactions in Combination Biological Drug Products
Pre-filled syringes (PFS) and autoinjectors are increasingly used to deliver biologic drug products, particularly monoclonal antibodies (mAbs), to improve convenience, compliance and dosing accuracy. However, these systems face performance and quality challenges such as needle clogging, particularly for high concentration, viscous, and aggregation-prone formulations. The origins and mechanisms by which device-derived leachables influence clogging and protein stability remain poorly understood. In this study, we investigated zinc (Zn) leaching from rigid needle shields (RNS) and its interactions with a high concentration dupilumab formulation and common excipients. ICP-MS quantification shows that Zn was the predominant metal in RNS batches, and their extraction kinetics depended strongly on time, temperature, and the presence of a routinely utilized surfactant, polysorbate 80 (PS-80). Stressing RNS materials in the dupilumab formulation at 40°C for 14 days yielded up to 550 µg/mL Zn(II), roughly 100-fold above typical specifications. Isothermal titration calorimetry (ITC) revealed millimolar Zn(II) binding to PS‑80 and weaker interaction with buffer components (histidine, arginine, and acetate), which together promote Zn release. Structural modeling identified surface-exposed regions of dupilumab enriched in histidine, sulfur-containing, and carboxylic acid-containing residues that are geometrically arranged to chelate Zn(II), highlighting likely Zn(II) binding motifs. These protein-metal and excipient-metal interactions, along with PS-80 degradation catalyzed by Zn, correlate with increased solution viscosity and formation of high molecular weight species. Zn leaching from RNS and its synergistic interactions with PS80, buffer components, and the mAb can drive PS-80 degradation, increase viscosity, and promote higher-order protein aggregation, factors that plausibly contribute to needle clogging. Overall, Zn can simultaneously interact with proteins, increasing their propensity to aggregate while degrading the excipients intended to stabilize them against aggregation. Understanding these mechanisms can inform candidate selection, formulation design and device choice to mitigate protein aggregation and syringe clogging and improve product reliability and therapeutic outcomes.
- 10 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanistic Investigation of Zn (II) Extraction and Interactions in Combination Biological Drug Products
Pre-filled syringes (PFS) and autoinjectors are increasingly used to deliver biologic drug products, particularly monoclonal antibodies (mAbs), to improve convenience, compliance and dosing accuracy. However, these systems face performance and quality challenges such as needle clogging, particularly for high concentration, viscous, and aggregation-prone formulations. The origins and mechanisms by which device-derived leachables influence clogging and protein stability remain poorly understood. In this study, we investigated zinc (Zn) leaching from rigid needle shields (RNS) and its interactions with a high concentration dupilumab formulation and common excipients. ICP-MS quantification shows that Zn was the predominant metal in RNS batches, and their extraction kinetics depended strongly on time, temperature, and the presence of a routinely utilized surfactant, polysorbate 80 (PS-80). Stressing RNS materials in the dupilumab formulation at 40°C for 14 days yielded up to 550 µg/mL Zn(II), roughly 100-fold above typical specifications. Isothermal titration calorimetry (ITC) revealed millimolar Zn(II) binding to PS‑80 and weaker interaction with buffer components (histidine, arginine, and acetate), which together promote Zn release. Structural modeling identified surface-exposed regions of dupilumab enriched in histidine, sulfur-containing, and carboxylic acid-containing residues that are geometrically arranged to chelate Zn(II), highlighting likely Zn(II) binding motifs. These protein-metal and excipient-metal interactions, along with PS-80 degradation catalyzed by Zn, correlate with increased solution viscosity and formation of high molecular weight species. Zn leaching from RNS and its synergistic interactions with PS80, buffer components, and the mAb can drive PS-80 degradation, increase viscosity, and promote higher-order protein aggregation, factors that plausibly contribute to needle clogging. Overall, Zn can simultaneously interact with proteins, increasing their propensity to aggregate while degrading the excipients intended to stabilize them against aggregation. Understanding these mechanisms can inform candidate selection, formulation design and device choice to mitigate protein aggregation and syringe clogging and improve product reliability and therapeutic outcomes.
- 25 February 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1747, 465818
Integration of QSAR models with high throughput screening to accelerate the development of polishing chromatography unit operations
- 25 February 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1747, 465818
Integration of QSAR models with high throughput screening to accelerate the development of polishing chromatography unit operations